194 research outputs found
Gene expression profiles link respiratory viral infection, platelet response to aspirin, and acute myocardial infarction
Background Influenza infection is associated with myocardial infarction (MI), suggesting that respiratory viral infection may induce biologic pathways that contribute to MI. We tested the hypotheses that 1) a validated blood gene expression signature of respiratory viral infection (viral GES) was associated with MI and 2) respiratory viral exposure changes levels of a validated platelet gene expression signature (platelet GES) of platelet function in response to aspirin that is associated with MI. Methods A previously defined viral GES was projected into blood RNA data from 594 patients undergoing elective cardiac catheterization and used to classify patients as having evidence of viral infection or not and tested for association with acute MI using logistic regression. A previously defined platelet GES was projected into blood RNA data from 81 healthy subjects before and after exposure to four respiratory viruses: Respiratory Syncytial Virus (RSV) (n=20), Human Rhinovirus (HRV) (n=20), Influenza A virus subtype H1N1 (H1N1) (n=24), Influenza A Virus subtype H3N2 (H3N2) (n=17). We tested for the change in platelet GES with viral exposure using linear mixed-effects regression and by symptom status. Results In the catheterization cohort, 32 patients had evidence of viral infection based upon the viral GES, of which 25% (8/32) had MI versus 12.2%(69/567) among those without evidence of viral infection (OR 2.3; CI [1.03-5.5], p=0.04). In the infection cohorts, only H1N1 exposure increased platelet GES over time (time course p-value = 1e-04). Conclusions A viral GES of non-specific, respiratory viral infection was associated with acute MI; 18% of the top 49 genes in the viral GES are involved with hemostasis and/or platelet aggregation. Separately, H1N1 exposure, but not exposure to other respiratory viruses, increased a platelet GES previously shown to be associated with MI. Together, these results highlight specific genes and pathways that link viral infection, platelet activation, and MI especially in the case of H1N1 influenza infection
Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with high morbidity, mortality, and health-care costs. An incomplete response to the anti-inflammatory effects of inhaled corticosteroids is present in COPD. Preclinical work indicates that 'low dose' theophylline improves steroid responsiveness. The Theophylline With Inhaled Corticosteroids (TWICS) trial investigates whether the addition of 'low dose' theophylline to inhaled corticosteroids has clinical and cost-effective benefits in COPD. METHOD/DESIGN: TWICS is a randomised double-blind placebo-controlled trial conducted in primary and secondary care sites in the UK. The inclusion criteria are the following: an established predominant respiratory diagnosis of COPD (post-bronchodilator forced expiratory volume in first second/forced vital capacity [FEV1/FVC] of less than 0.7), age of at least 40 years, smoking history of at least 10 pack-years, current inhaled corticosteroid use, and history of at least two exacerbations requiring treatment with antibiotics or oral corticosteroids in the previous year. A computerised randomisation system will stratify 1424 participants by region and recruitment setting (primary and secondary) and then randomly assign with equal probability to intervention or control arms. Participants will receive either 'low dose' theophylline (Uniphyllin MR 200 mg tablets) or placebo for 52 weeks. Dosing is based on pharmacokinetic modelling to achieve a steady-state serum theophylline of 1-5 mg/l. A dose of theophylline MR 200 mg once daily (or placebo once daily) will be taken by participants who do not smoke or participants who smoke but have an ideal body weight (IBW) of not more than 60 kg. A dose of theophylline MR 200 mg twice daily (or placebo twice daily) will be taken by participants who smoke and have an IBW of more than 60 kg. Participants will be reviewed at recruitment and after 6 and 12 months. The primary outcome is the total number of participant-reported COPD exacerbations requiring oral corticosteroids or antibiotics during the 52-week treatment period. DISCUSSION: The demonstration that 'low dose' theophylline increases the efficacy of inhaled corticosteroids in COPD by reducing the incidence of exacerbations is relevant not only to patients and clinicians but also to health-care providers, both in the UK and globally. TRIAL REGISTRATION: Current Controlled Trials ISRCTN27066620 was registered on Sept. 19, 2013, and the first subject was randomly assigned on Feb. 6, 2014
ĐŃОйНивОŃŃŃ ŃĐžŃĐźŃĐ˛Đ°Đ˝Đ˝Ń ŃаПОŃŃŃĐšĐ˝ĐžŃ ĐżŃСнаваНŃĐ˝ĐžŃ Đ´ŃŃĐťŃнОŃŃŃ ĐźĐ°ĐšĐąŃŃĐ˝ŃŃ ŃŃиŃоНŃв ПаŃоПаŃики
(uk) ĐŁ ŃŃĐ°ŃŃŃ ĐˇŃОйНонО ŃĐżŃĐžĐąŃ ŃОСкŃиŃи ĐžŃОйНивОŃŃŃ ŃаПОŃŃŃĐšĐ˝ĐžŃ ĐżŃСнаваНŃĐ˝ĐžŃ Đ´ŃŃĐťŃнОŃŃŃ ĐźĐ°ĐšĐąŃŃĐ˝ŃŃ
вŃиŃоНŃв; Đ´ĐžŃĐťŃĐ´ĐśŃŃŃŃŃŃ ŃŃĐˇĐ˝Ń ĐżŃĐ´Ń
Оди Đ´Đž ŃŃОгО пОнŃŃŃŃ; ŃОСкŃиваŃŃŃŃŃ ŃĐ°ĐşŃ ĐšĐžĐłĐž ŃкНадОвŃ, ŃĐş ŃаПОŃŃŃКнŃŃŃŃ, ĐżŃСнаваНŃна ŃаПОŃŃŃКнŃŃŃŃ, ĐżŃСнаваНŃна Đ´ŃŃĐťŃĐ˝ŃŃŃŃ.(ru) Đ ŃŃĐ°ŃŃĐľ ŃдоНана пОпŃŃка ŃĐ°ŃĐşŃŃŃŃ ĐžŃОйоннОŃŃи ŃаПОŃŃĐžŃŃоНŃнОК пОСнаваŃоНŃнОК Đ´ĐľŃŃоНŃнОŃŃи ĐąŃĐ´ŃŃиŃ
ŃŃиŃоНоК; иŃŃНодŃŃŃŃŃ ŃаСНиŃĐ˝ŃĐľ пОдŃ
ĐžĐ´Ń Đş ŃŃĐžĐźŃ ĐżĐžĐ˝ŃŃиŃ; ŃĐ°ŃĐşŃŃваŃŃŃŃ Ńакио огО ŃĐžŃŃавНŃŃŃио, как ŃаПОŃŃĐžŃŃоНŃнОŃŃŃ, пОСнаваŃоНŃĐ˝Đ°Ń ŃаПОŃŃĐžŃŃоНŃнОŃŃŃ, пОСнаваŃоНŃĐ˝Đ°Ń Đ´ĐľŃŃоНŃнОŃŃŃ
Characterization of Serum Proteins Associated with IL28B Genotype among Patients with Chronic Hepatitis C
Introduction: Polymorphisms near the IL28B gene (e.g. rs12979860) encoding interferon lambda 3 have recently been associated with both spontaneous clearance and treatment response to pegIFN/RBV in chronic hepatitis C (CHC) patients. The molecular consequences of this genetic variation are unknown. To gain further insight into IL28B function we assessed the association of rs12979860 with expression of protein quantitative traits (pQTL analysis) generated using open-platform proteomics in serum from patients
The malarial exported PFA0660w is an Hsp40 co-chaperone of PfHsp70-x
Plasmodium falciparum, the human pathogen responsible for the most dangerous malaria infection, survives and develops in mature erythrocytes through the export of proteins needed for remodelling of the host cell. Molecular chaperones of the heat shock protein (Hsp) family are prominent members of the exportome, including a number of Hsp40s and a Hsp70. PFA0660w, a type II Hsp40, has been shown to be exported and possibly form a complex with PfHsp70-x in the infected erythrocyte cytosol. However, the chaperone properties of PFA0660w and its interaction with human and parasite Hsp70s are yet to be investigated. Recombinant PFA0660w was found to exist as a monomer in solution, and was able to significantly stimulate the ATPase activity of PfHsp70-x but not that of a second plasmodial Hsp70 (PfHsp70-1) or a human Hsp70 (HSPA1A), indicating a potential specific functional partnership with PfHsp70-x. Protein binding studies in the presence and absence of ATP suggested that the interaction of PFA0660w with PfHsp70-x most likely represented a co-chaperone/chaperone interaction. Also, PFA0660w alone produced a concentrationdependent suppression of rhodanese aggregation, demonstrating its chaperone properties. Overall, we have provided the first biochemical evidence for the possible role of PFA0660w as a chaperone and as co-chaperone of PfHsp70-x. We propose that these chaperones boost the chaperone power of the infected erythrocyte, enabling successful protein trafficking and folding, and thereby making a fundamental contribution to the pathology of malaria
Gibberellin A1 Metabolism Contributes to the Control of Photoperiod-Mediated Tuberization in Potato
Some potato species require a short-day (SD) photoperiod for tuberization, a process that is negatively affected by gibberellins (GAs). Here we report the isolation of StGA3ox2, a gene encoding a GA 3-oxidase, whose expression is increased in the aerial parts and is repressed in the stolons after transfer of photoperiod-dependent potato plants to SD conditions. Over-expression of StGA3ox2 under control of constitutive or leaf-specific promoters results in taller plants which, in contrast to StGA20ox1 over-expressers previously reported, tuberize earlier under SD conditions than the controls. By contrast, StGA3ox2 tuber-specific over-expression results in non-elongated plants with slightly delayed tuber induction. Together, our experiments support that StGA3ox2 expression and gibberellin metabolism significantly contribute to the tuberization time in strictly photoperiod-dependent potato plants
Predicting the impact of Lynch syndrome-causing missense mutations from structural calculations
Accurate methods to assess the pathogenicity of mutations are needed to fully leverage the possibilities of genome sequencing in diagnosis. Current data-driven and bioinformatics approaches are, however, limited by the large number of new variations found in each newly sequenced genome, and often do not provide direct mechanistic insight. Here we demonstrate, for the first time, that saturation mutagenesis, biophysical modeling and co-variation analysis, performed in silico, can predict the abundance, metabolic stability, and function of proteins inside living cells. As a model system, we selected the human mismatch repair protein, MSH2, where missense variants are known to cause the hereditary cancer predisposition disease, known as Lynch syndrome. We show that the majority of disease-causing MSH2 mutations give rise to folding defects and proteasome-dependent degradation rather than inherent loss of function, and accordingly our in silico modeling data accurately identifies disease-causing mutations and outperforms the traditionally used genetic disease predictors. Thus, in conclusion, in silico biophysical modeling should be considered for making genotype-phenotype predictions and for diagnosis of Lynch syndrome, and perhaps other hereditary diseases
- âŚ